These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 25542074)

  • 1. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.
    Darwish M; Bond M; Tracewell W; Robertson P; Yang R
    Clin Drug Investig; 2015 Jan; 35(1):13-22. PubMed ID: 25391549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects.
    Bond M; Rabinovich-Guilatt L; Selim S; Darwish M; Tracewell W; Robertson P; Yang R; Malamut R; Colucci P; Ducharme MP; Spiegelstein O
    Clin Drug Investig; 2017 Dec; 37(12):1153-1163. PubMed ID: 28948482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA(®) Abuse Deterrence Technology.
    Darwish M; Bond M; Yang R; Tracewell W; Robertson P
    Clin Drug Investig; 2015 Oct; 35(10):645-52. PubMed ID: 26369654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Drug Investig; 2015 May; 35(5):291-7. PubMed ID: 25813216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
    Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
    BMC Pharmacol Toxicol; 2015 Nov; 16():31. PubMed ID: 26614499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
    Darwish M; Bond M; Ma Y; Tracewell W; Robertson P; Webster LR
    Pain Med; 2017 Jan; 18(1):61-77. PubMed ID: 27330154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Pharmacol Drug Dev; 2016 Mar; 5(2):141-9. PubMed ID: 27138027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain.
    Robinson CY; Rubino CM; Farr SJ
    J Opioid Manag; 2015; 11(5):405-15. PubMed ID: 26535968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
    Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
    Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
    Bond M; Schoedel KA; Rabinovich-Guilatt L; Gasior M; Tracewell W; Malamut R; Ma Y; Webster LR
    Pain Med; 2018 Aug; 19(8):1597-1612. PubMed ID: 29016880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
    Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
    Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Profile and Sustained 24-hour Analgesia of a Once-daily Hydrocodone Bitartrate Extended-release Tablet with Abuse-deterrent Properties.
    Kapil RP; Cipriano A; Wen W; Yu Lynch S; He E; Colucci SV; Harris SC
    Clin Ther; 2016 Feb; 38(2):302-14. PubMed ID: 26749219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
    Hale ME; Ma Y; Malamut R
    J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label pharmacokinetic study of oxymorphone extended release in the presence of naltrexone in the older adult.
    Pergolizzi JV; Raffa RB; Taylor R; Nagar S; Labhsetwar S; Sinclair N; Gould EM
    J Opioid Manag; 2012; 8(6):383-93. PubMed ID: 23264316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.
    Hale ME; Zimmerman TR; Eyal E; Malamut R
    J Opioid Manag; 2015; 11(6):507-18. PubMed ID: 26728648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers.
    Darwish M; Hellriegel ET
    Clin Ther; 2011 Jun; 33(6):746-53. PubMed ID: 21704239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.